Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) —— Plans to engage with the U.S. Food and Drug Administration (FDA) to gain alig…